Gefitinib is a first-generation EGFR-TKI, which has good efficacy and tolerance for lung adenocarcinoma patients with EGFR-sensitive mutations and has been included in the Chinese medical insurance directory [8]. Here, EGFR is linked to lung adenocarcinoma.